Phase 3 Readout~month

Phase 3 Topline: A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostini

Indication
Pulmonary Arterial Hypertension; Pulmonary Hypertension Due to Lung Diseases

Other upcoming events for LQDA

Phase 3 ReadoutPhase 3 Topline: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety
Patent ExpiryPatent/Exclusivity Expiry: YUTREPIA

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start FreeFull Calendar
    Phase 3 Topline: A Phase 3, 2-Part, Open-Label Study to Evaluate the Safety and Tolerability of Liposomal Treprostini — LQDA Phase 3 Readout | BioSniper